screenshot of PhRMA blog post September 15, 2022
Headline from recent blog post by PhRMA spokesperson Nicole Longo.

PhRMA, BIO, and Others Unleash a Torrent of 340B Hospital Criticism

340B disproportionate share hospitals (DSH) in 2020 spent 2.2 times more on outpatient drugs per commercially insured patient than non-340B DSH hospitals and 2.6 times more than other types of 340B hospitals, a new drug industry-funded study shows.

The Sept. 15 study commissioned by Pharmaceutical Research and Manufacturers of America (PhRMA) was just one of several punches that critics of 340B hospitals have thrown recently. Biotechnology Innovation Organization, Community Oncology Alliance, and American Action Forum also issued studies or published articles finding fault with 340B hospitals and calling for major changes to the drug discount program.

340B disproportionate share hospitals (DSH) in 2020 spent 2.2 times more on outpatient drugs per commercially insured patient than non-340B DSH hospitals and 2.6 times more than other types of 340B hospitals, a new drug industry-funded study shows.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer